ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
2seventy bio Inc

2seventy bio Inc (TSVT)

4.34
-0.26
( -5.65% )
Updated: 13:34:11

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.501.704.402.403.050.000.00 %00-
5.000.000.000.000.000.000.00 %00-

Empower your portfolio: Real-time discussions and actionable trading ideas.

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.500.050.050.050.050.000.00 %01-
5.000.450.850.500.650.000.00 %040-

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BTCTBTC Digital Ltd
US$ 10.54
(318.25%)
113.63M
MULNMullen Automotive Inc
US$ 3.175
(85.67%)
47.72M
PAMTPAMT Corporation
 21.85
(73.28%)
47.32k
LGMKLogicMark Inc
US$ 0.20315
(52.74%)
518.36M
AGFYAgrify Corporation
US$ 7.21
(49.28%)
978.35k
NGNENeurogene Inc
US$ 38.31
(-46.44%)
1.22M
STIMNeuronetics Inc
US$ 0.681
(-38.09%)
5.89M
RAILFreightCar America Inc
US$ 9.915
(-36.89%)
2M
RMTIRockwell Medical Inc
US$ 2.97
(-36.13%)
5.08M
PGYPagaya Technologies Ltd
US$ 10.95
(-35.17%)
10.04M
CEROCERo Therapeutics Holdings Inc
US$ 0.272899
(39.23%)
667.73M
LGMKLogicMark Inc
US$ 0.20315
(52.74%)
518.36M
LIFWMSP Recovery Inc
US$ 0.12
(-5.29%)
164.47M
NVDANVIDIA Corporation
US$ 148.5001
(2.23%)
145.68M
ELABElevai Labs Inc
US$ 0.0189
(-2.07%)
126.65M

TSVT Discussion

View Posts
Monksdream Monksdream 2 months ago
TSVT under $5
👍️0
Monksdream Monksdream 7 months ago
TSVT under $5
👍️0
Invest-in-America Invest-in-America 8 months ago
TSVT: Big (Post-M) news for this Firm & partner Bristol Myers.

"Bristol Myers, 2seventy Bios Cancer Treatment Wins FDA Committee Approval
7:04 PM ET 3/15/24 | Dow Jones
By Ben Glickman Bristol Myers Squibb and 2seventy Bio's cancer treatment showed a favorable risk-benefit profile in certain populations, according to Food and Drug Administration committee. The Oncologic Drugs Advisory Committee voted 8-3 that Abecma, a gene therapy, had a favorable profile in the treatment of the blood cancer multiple myeloma, specifically in the triple-class exposed relapsed or refractory forms of the cancer, the companies said on Friday. Bristol Myers Squibb and 2seventy said the recommendation would be considered by the FDA in its review of their supplemental Biologics License Application. The FDA hasn't assigned a new target action date for reviewing that application, the companies said. Abecma was recently approved in Japan and Switzerland for patients with relapsed or refractory multiple myeloma who have received at least two prior therapies. Write to Ben Glickman at ben.glickman@wsj.com > Dow Jones Newswires March 15, 2024 19:04 ET (23:04 GMT)"
👍️0
Monksdream Monksdream 8 months ago
TSVT 10Q due March 5
👍️0
molee molee 9 months ago
$TSVT > A bit of "short covering" going on now ... How high ???
👍️0
Monksdream Monksdream 11 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👎️ 1
johnhancoque johnhancoque 12 months ago
2 seventy will be auctioned off in Bankruptcy court within a year. Cash on hand is 12 months or less.
👍️0
molee molee 1 year ago
C'mon man . What the heck . $2.00 now ? Really ?
👍️0